These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38313312)

  • 1. Towards a better detection of patients at-risk of linezolid toxicity in clinical practice: a prospective study in three Belgian hospital centers.
    Thirot H; Fage D; Leonhardt A; Clevenbergh P; Besse-Hammer T; Yombi JC; Cornu O; Briquet C; Hites M; Jacobs F; Wijnant GJ; Wicha SG; Cotton F; Tulkens PM; Spinewine A; Van Bambeke F
    Front Pharmacol; 2024; 15():1310309. PubMed ID: 38313312
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers.
    Thirot H; Briquet C; Frippiat F; Jacobs F; Holemans X; Henrard S; Tulkens PM; Spinewine A; Van Bambeke F
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34064418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Increased Linezolid Plasma Concentrations and the Development of Severe Toxicity in Multidrug-Resistant Tuberculosis Treatment.
    Eimer J; Fréchet-Jachym M; Le Dû D; Caumes E; El-Helali N; Marigot-Outtandy D; Mechai F; Peytavin G; Pourcher V; Rioux C; Yazdanpanah Y; Robert J; Guglielmetti L;
    Clin Infect Dis; 2023 Feb; 76(3):e947-e956. PubMed ID: 35717636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study.
    Cojutti PG; Merelli M; Bassetti M; Pea F
    J Antimicrob Chemother; 2019 Dec; 74(12):3588-3595. PubMed ID: 31504570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
    Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
    J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions.
    Cheng CN; Wu CC; Kuo CH; Wang CC; Wang JT; Lin YT; Jhang RS; Lin SW
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):466-475. PubMed ID: 32600864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.
    Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K
    J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis.
    Liu X; Aoki M; Osa S; Ito C; Saiki R; Nagai T; Enoki Y; Taguchi K; Matsumoto K
    BMC Pharmacol Toxicol; 2022 Nov; 23(1):89. PubMed ID: 36451204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
    Crass RL; Cojutti PG; Pai MP; Pea F
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematological toxicities associated with linezolid therapy in adults: key findings and clinical considerations.
    Cattaneo D; Marriott DJ; Gervasoni C
    Expert Rev Clin Pharmacol; 2023 Mar; 16(3):219-230. PubMed ID: 36787631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
    Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
    BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose optimisation of linezolid in critically ill patients based on a population pharmacokinetic model: A two-centre prospective interventional study.
    Shi L; Zhang Y; Duan L; Huang L; Li J; Lu J; Zhuang Z; Yuan Y; Feng Z; Sun J; Liu X; Zhou Q; Xue H; Xu J; Tang L
    Int J Antimicrob Agents; 2023 Aug; 62(2):106881. PubMed ID: 37301313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical efficacy and safety of vancomycin compared with linezolid for the treatment of neonatal gram-positive bacterial sepsis].
    Tang L; Fang J; Wang SN; Weng XH; Li JJ; Shang EN
    Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):686-91. PubMed ID: 27596084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study.
    Liu T; Yuan Y; Wang C; Wu J; Wang Y; Na P; Chen X; Rao W; Zhao J; Wang D; Wang H; Duan Z; Xie F; Fang X; Xie L; Li H
    J Antimicrob Chemother; 2024 Jun; ():. PubMed ID: 38873816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring Coupled With Bayesian Forecasting Could Prevent Vancomycin-Associated Nephrotoxicity in Renal Insufficiency Patients: A Prospective Study and Pharmacoeconomic Analysis.
    Zhang Y; Wang T; Zhang D; You H; Dong Y; Liu Y; Du Q; Sun D; Zhang T; Dong Y
    Ther Drug Monit; 2020 Aug; 42(4):600-609. PubMed ID: 32097248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.
    Matsumoto K; Takeshita A; Ikawa K; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    Int J Antimicrob Agents; 2010 Aug; 36(2):179-81. PubMed ID: 20392606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.
    Dai Y; Jiang S; Chen X; Han L; Zhang C; Yu X; Zhang X
    J Clin Pharm Ther; 2021 Jun; 46(3):807-813. PubMed ID: 33555057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients.
    Dong HY; Xie J; Chen LH; Wang TT; Zhao YR; Dong YL
    Eur J Clin Microbiol Infect Dis; 2014 Jun; 33(6):1029-35. PubMed ID: 24515096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictive performance of population pharmacokinetic software on vancomycin steady-state trough concentration].
    Xue S; Lu H; Tang L; Fang J; Shi L; Li J; Yu Y; Zhou Q; Xue S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jan; 32(1):50-55. PubMed ID: 32148231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.